# Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal Naloxone

> **NCT04764630** · PHASE1 · COMPLETED · sponsor: **Food and Drug Administration (FDA)** · enrollment: 21 (actual)

## Conditions studied

- Healthy Subjects
- Opioid Antagonist
- Pharmacokinetics

## Interventions

- **DRUG:** Four naloxone nasal spray doses (1 every 2.5 min)
- **DRUG:** Four naloxone nasal spray doses (2 every 2.5 min)
- **DRUG:** Two naloxone nasal spray doses (1 every 2.5 min)

## Key facts

- **NCT ID:** NCT04764630
- **Lead sponsor:** Food and Drug Administration (FDA)
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-01
- **Primary completion:** 2021-03-20
- **Final completion:** 2021-03-20
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04764630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04764630, "Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal Naloxone". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04764630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*